Vortioxetine in major depressive disorder : from mechanisms of action to clinical studies. An updated review

Javier de Diego-Adeliño, José Manuel Crespo, Fernando Mora, Adrián Neyra, Pedro Iborra, Luis Gutiérrez-Rojas, Selman F. Salonia

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

29 Cites (Scopus)

Resum

Introduction: Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials. Areas covered: The present review intends to gather the most relevant and pragmatic data of vortioxetine in MDD, specially focusing on new studies that emerged between 2015 and 2020. Expert opinion: Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT receptor, partial agonism of 5-HT receptor, and antagonism of 5-HT, 5-HT and 5-HT receptors). This new mechanism of action can explain the dose-dependent effect and can be responsible for its effects on cognitive functioning and improved tolerability profile. Potential analgesic and anti-inflammatory properties observed in preclinical studies as well as interesting efficacy and tolerability results of clinical studies with specific target groups render it a promising therapeutic option for patients with MDD and concomitant conditions (as menopause symptoms, pain, inflammation, apathy, sleep and/or metabolic abnormalities).
Idioma originalAnglès
Pàgines (de-a)0673-690
Nombre de pàgines18
RevistaExpert Opinion on Drug Safety
Volum21
Número5
DOIs
Estat de la publicacióPublicada - 2022

Fingerprint

Navegar pels temes de recerca de 'Vortioxetine in major depressive disorder : from mechanisms of action to clinical studies. An updated review'. Junts formen un fingerprint únic.

Com citar-ho